Evidence map›Paper›PMID 32068011›Full record

ReviewJournal of neuroscience methods2020

Novel ablation methods for treatment of gliomas.

Brittanie Partridge, John H Rossmeisl, Alexandra M Kaloss, Erwin Kristobal Gudenschwager Basso, Michelle H Theus

Open access · greenAbstract readReview
In one paragraph

Review in Journal of neuroscience methods, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Brittanie PartridgeVeterinary and Comparative Neuro-oncology Laboratory, Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, 24061, USA.
John H RossmeislVeterinary and Comparative Neuro-oncology Laboratory, Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, 24061, USA.
Alexandra M KalossDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA.
Erwin Kristobal Gudenschwager BassoDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA.
Michelle H TheusDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA; School of Neuroscience, Virginia Tech, Blacksburg VA 24061, USA; Center for Regenerative Medicine, VT College of Veterinary Medicine, Blacksburg, Virginia, 24061, USA. Electronic address: mtheus@vt.edu.
Virginia–Maryland College of Veterinary Medicine · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBMP01CA207206 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DEBINSKI, WALDEMAR · 2017 to 2021
$9.0M
High-frequency Irreversible Electroporation (H-FIRE) combinatorial GBM treatmentR01CA213423 · NCI · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI DAVALOS, RAFAEL VIDAL, VERBRIDGE, SCOTT S · 2017 to 2021
$1.7M
Molecular Combinatorial Therapy of Glioblastoma MultiformeR01CA139099 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DEBINSKI, WALDEMAR · 2010 to 2014
$1.5M
NCI NIH HHS P01 CA207206NCI NIH HHS P30 CA012197NCI NIH HHS R01 CA139099NCI NIH HHS R01 CA213423
6 · The paper itself

Abstract

Primary brain tumors are among the deadliest cancers that remain highly incurable. A need exists for new approaches to tumor therapy that can circumvent the blood brain barrier (BBB), target highly resistant tumors and cancer stem-like cells (CSCs) as well create an anti-cancer immunomodulatory environment. Successful treatments may also require a combinatory approach utilizing surgery, chemotherapy, radiation and novel ablation strategies that can both eliminate the bulk tumor and prevent any potential residual CSCs from propagating in the resected tissue. A number of thermal and non-thermal ablation methods have been developed and tested, which have gained much enthusiasm for the treatment of brain tumors. Here we review the most common primary brain tumors and the candidate ablation methods for targeting the tumor and its microenvironment.

Indexed as

Brain NeoplasmsGliomaBlood-Brain BarrierDisease ProgressionHumansNeoplastic Stem CellsTumor MicroenvironmentBrain tumorCancer stem cellsGFAPH-FIREHistotripsyIRELaser and radiofrequency ablationSox2

Identifiers

PMID32068011
PMCPMC8067884
OpenAlexW3006524402

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.